Igyxos focuses on all stages of development, from discovering potential targets to acquiring intellectual property rights and advancing drugs and technologies to the development phase. Their unique approach involves identifying and enhancing the activity of gonadotropins and hormones using monoclonal antibodies, aiming to significantly improve fertility treatment outcomes. They are pioneering novel therapeutics to transform the treatment of infertility by addressing hormonal imbalances through the use of monoclonal antibodies.